A phase I, open-label, dose-escalation, multidose study of CDX-1307, a mannose receptor-targeted hCG-beta vaccine, in patients with incurable locally advanced or metastatic breast, colorectal, pancreatic, bladder and ovarian cancer.

Trial Profile

A phase I, open-label, dose-escalation, multidose study of CDX-1307, a mannose receptor-targeted hCG-beta vaccine, in patients with incurable locally advanced or metastatic breast, colorectal, pancreatic, bladder and ovarian cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2010

At a glance

  • Drugs CDX 1307 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jul 2010 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov.
    • 23 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Oct 2009 Positive results were presented at the 24th Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top